biologics, | press-releases, | Knowledge Center | FDLI.org

Tobacco Control Act Substantial Equivalence Rebuttal Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on April 2013 by Michael Levin-Epstein

Adverse Event Reporting and Distinct Naming of Biosimilars Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on March 2013 by Michael Levin-Epstein

Prohibition on Use of Chimpanzees for Biomedical Research Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on March 2013 by Michael Levin-Epstein

Implementing Physician Payment Sunshine Act Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on February 2013 by Michael Levin-Epstein

Consequences of Landmark Second Circuit Decision in United States v. Caronia Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on February 2013 by Michael Levin-Epstein

Unique Names for All Biologics and Biosimilars Rebuttal Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on January 2013 by Michael Levin-Epstein

Unique Names for All Biologics and Biosimilars Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on November 2012 by Michael Levin-Epstein

Punishing Unlawful Prescription Drug Promotion Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on October 2012 by Michael Levin-Epstein

DIA and FDLI Collaborate in Conference to Examine User Fees

Posted on August 2012 by Michael Levin-Epstein

Food and Drug Law Institute To Hold Conference on U.S.-Brazil Food and Drug Law

Posted on August 2012 by MIchael Levin-Epstein

1
2

more